News
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
11don MSN
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...
Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...
Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...
After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback